



Antimicrobial susceptibility

Antibiotic susceptibility of clinically relevant anaerobes in Estonia from 1999 to 2001[☆]Krista Lõivukene^{a,b,*}, Paul Naaber^{a,b}^a Department of Clinical Microbiology, United Laboratories, Puusepa 1A, Tartu, Estonia^b Department of Microbiology, Tartu University, Tartu, Estonia

Received 30 August 2002; received in revised form 11 February 2003; accepted 16 February 2003

Abstract

At present little or no data is available regarding the resistance profiles of anaerobic bacteria in relation to the general usage of antibiotics. The objective of this study was to assess whether any potential relationship exists between the dynamics of antibiotic resistance of anaerobic bacteria and the consumption of antibiotics during the last 3 years within the Estonian population.

In total, 416 anaerobic isolates were investigated from various clinical samples. The anaerobes were isolated on Wilkins-Chalgren Agar, incubated in an anaerobic glove box and identified by standard methods. β -lactamase negative strains were tested against metronidazole, clindamycin, benzylpenicillin and the positive strains were further tested against metronidazole, clindamycin, and ampicillin/sulbactam by E-tests. The results of the susceptibility tests were interpreted according to the current criteria of NCCLS. Data from the Estonian State Agency of Medicines was used to assess the antibiotic consumption rate in the population (Defined Daily Doses per 1000 inhabitants annually).

The following species of anaerobes were isolated: *B. fragilis* group, *Bacteroides* sp., *Fusobacterium* sp., *Porphyromonas* sp., *Prevotella* sp., *Peptostreptococcus* sp., in addition to various unidentified Gram-positive rods.

Metronidazole resistance was not found among Gram-negative bacteria despite a relatively high consumption of this antimicrobial agent in Estonia. Only ampicillin/sulbactam demonstrated excellent in vitro activity against all anaerobes. Unexpectedly despite a relatively low rate of consumption of clindamycin a high rate of resistance to this agent occurred; a similar situation was noted for penicillin.

In the present study we did not observe a relationship between the changes in antibiotic consumption (DDD/1000) rate and the resistance pattern of anaerobic bacteria to metronidazole, clindamycin, penicillin and ampicillin/sulbactam during a 3-year follow-up period. High resistance to penicillin among some species and also to clindamycin is similar to the global trend and argues for limited use of these antibiotics in empirical treatment. We would suggest that monitoring of local susceptibility pattern is necessary for the selection of initial empirical therapy.

© 2003 Elsevier Science Ltd. All rights reserved.

Keywords: Anaerobic bacteria; Antibiotic susceptibility and antibiotic consumption

1. Introduction

Anaerobic bacteria play an important role in the pathogenicity of mixed aerobic–anaerobic infections, mainly as intra-abdominal and gynecologic infections. The majority of anaerobic infections arise from the

indigenous flora of the host [1]. There is a general agreement that increasing antimicrobial resistance is related to the selective pressure exerted by the use of antibiotics [2]. Therefore, the susceptibility pattern of anaerobes may be reflected in the general consumption of antibiotics. No data comparing the resistance of anaerobic bacteria to different antimicrobial agents with the dynamics of antibiotic consumption in the population is currently available.

A significant level of resistance to clindamycin, cephalosporins, penicillins, and β -lactam antibiotics has been reported among anaerobic bacteria [3].

[☆]Paper from Anaerobe Olympiad 2002. The 6th Biennial Congress of the Anaerobe Society of the Americas, Park City, Utah, 29 June–2 July.

*Corresponding author. Tel.: +372-7319-326; fax: +372-7319-339.
E-mail address: krista.loivuke@kliinikum.ee (K. Lõivukene).

Although still rare, resistance of *Bacteroides* sp. to metronidazole has been reported sporadically since 1978 [4].

Since susceptibility testing of anaerobes is both time consuming and expensive, therapy is often guided by local patterns of published susceptibility reports. However, the local patterns may differ significantly and dynamic changes of resistance pattern for particular anaerobes may occur.

In the present work, the first objective was to assess the prevalence of anaerobic pathogens and their susceptibility pattern in Estonia from 1999 to 2001. The second goal was to assess any potential relationship between the susceptibility pattern and the rate of antibiotic use over the course of 3 years.

2. Materials and methods

A total of 47, 178 and 191 consecutive strains of anaerobic bacteria (a total of 416) were isolated from abscesses, deep and superficial wounds, and paranasal sinus secretions clinical materials in 1999, 2000 and 2001, respectively. Strains were collected in an anaerobic Stuart Transport Medium and taken to the laboratory within 2 h. The anaerobes were isolated on Wilkins-Chalgren Agar (Oxoid, Basingstoke, Hampshire, UK) supplemented with 5% horse blood and incubated in an anaerobic chamber (Sheldon Manufacturing Inc., Cornelius, Oregon, USA) under anaerobic conditions (with gas mixture: 5% CO₂, 5% H₂, 90% N₂) for 2–4 days. Aerotolerance testing was performed using chocolate agar plates (Oxoid) in a 5–10% CO₂ atmosphere. Identification was performed according to colony and cellular morphology, potency disk pattern, and biochemical profiles [5].

Susceptibility tests were performed and interpreted according to the current criteria of NCCLS.

The production of β -lactamase was determined with nitrocefin disks (AB Biodisk, Solna, Sweden). For susceptibility testing, a suspension in 0.9% sodium chloride solution (2 mL) was prepared equivalent to no. 1 McFarland turbidity standard. The suspension was subsequently transferred onto the surface of a Wilkins-Chalgren Agar (Oxoid) plate and streaked with a cotton swab. Antibiotic strips (E-tests AB Biodisk, Solna, Sweden) were applied onto the surface of each dried agar plate. The plates were incubated in an anaerobic chamber (Sheldon Manufacturing Inc.) at 37°C for 48 h prior to examination. β -Lactamase-negative strains were further tested for resistance to metronidazole, clindamycin, benzylpenicillin and positive strains tested against metronidazole, clindamycin, and ampicillin/sulbactam. Data from the Estonian State Agency of Medicines was used to assess the antibiotic consumption rate in the population (DDD/1000/annually).

Table 1
Distribution of anaerobic isolates from 1999 to 2001

Organism	No. of isolates	% of total
<i>Bacteroides fragilis</i> group	86	20.7
<i>Bacteroides</i> sp.	81	19.5
<i>Fusobacterium</i> sp.	66	15.9
<i>Porphyromonas</i> sp.	16	3.8
<i>Prevotella</i> sp.	59	14.2
<i>Peptostreptococcus</i> sp.	97	23.3
Gram-positive rods ^a	11	2.6
Total	416	100

^a *Clostridium* sp. (six strains), *Propionibacterium* sp. (two strains), *Eubacterium* sp. (three strains).

3. Results

The distribution and frequency of test isolates are depicted in Table 1. Seventy-four percent were anaerobic Gram-negative bacilli (predominantly *B. fragilis* group), and 23% were Gram-positive cocci (*Peptostreptococcus* sp.), whereas Gram-positive rods occurred rarely.

The results of susceptibility tests prepared in different years are listed in Table 2. The spectrum of pathogenic bacteria and their susceptibility patterns in 1999 and in 2001 was similar. Overall, the isolated anaerobes were susceptible to the majority of antimicrobial agents tested. Metronidazole resistance was not found among Gram-negative rods, despite high resistance of Gram-positive anaerobic cocci and rods. The lowest activity occurred with penicillin and the highest with ampicillin/sulbactam. No differences were found between the resistance rates of anaerobes for the 3-year time period.

β -lactamase production was 48.8% for the *B. fragilis* group, 40.7% for *Bacteroides* sp., 22.7% for *Fusobacterium* sp., 37.5% for *Porphyromonas* sp., 62.7% for *Prevotella* sp., 18.6% for *Peptostreptococcus* sp. and 18.2% for Gram-positive rods.

The consumption rates of some antibiotics in Estonia during 1999, 2000, and 2001 are presented in Table 3. Metronidazole was the most frequently used anti-anaerobic antibiotic. The dynamics of consumption of these antibiotics was different. The use of metronidazole and penicillin was quite stable, whereas the use of clindamycin and ampicillin/sulbactam increased approximately two-fold.

The comparison of antibiotic consumption and the total percentage of the resistance among all tested anaerobic bacteria is presented in Fig. 1.

4. Discussion and conclusion

Antimicrobial resistance among both aerobes and anaerobes is a growing health problem worldwide. Within European countries the European Antimicrobial

Table 2
The susceptibility pattern (MIC₅₀ and MIC₉₀ mg/L) and β -lactamase production of anaerobic bacteria in 1999, 2000, and 2001

Species	Year	No. of strains/ β -lactamase- positive strains	MIC (mg/L)									
			Metronidazole		Clindamycin		Penicillin ^a		Ampicillin ^b /sulbactam			
			MIC ₅₀	MIC ₉₀	MIC ₅₀	MIC ₉₀	MIC ₅₀	MIC ₉₀	MIC ₅₀	MIC ₉₀		
<i>B. fragilis</i> group	1999	9	4	0.5	1.0	1.5	256.0	8.0	8.0	0.38	0.75	
	2000	45	21	0.023	1.0	0.032	256.0	8.0	256.0	1.0	3.0	
	2001	32	17	0.19	0.5	0.094	256.0	6.0	64.0	0.25	0.5	
<i>Bacteroides</i> sp.	1999	15	8	0.094	0.5	0.016	0.094	0.016	0.032	0.19	0.19	
	2000	35	12	0.047	0.19	0.016	0.064	0.016	16.0	0.032	0.25	
	2001	31	13	0.032	0.5	0.016	1.5	0.016	24.0	0.19	0.75	
<i>Fusobacterium</i> sp.	1999	4	1	0.016	0.032	0.016	0.016	0.016	0.023	2.0	2.0	
	2000	25	6	0.016	0.064	0.016	0.19	0.016	3.0	0.094	2.0	
	2001	37	8	0.023	0.125	0.016	0.25	0.016	0.094	0.016	0.064	
<i>Porphyromonas</i> sp.	1999	3	1	0.064	0.19	0.016	0.016	0.016	0.016	0.016	0.016	
	2000	4	1	4.0	4.0	0.016	4.0	0.016	256.0	0.25	0.25	
	2001	9	4	0.016	0.094	0.016	0.016	0.016	0.032	0.125	0.5	
<i>Prevotella</i> sp.	1999	5	3	0.016	0.5	0.016	0.032	0.016	6.0	0.016	0.016	
	2000	19	13	0.016	0.125	0.016	0.023	0.016	1.5	0.094	0.25	
	2001	35	21	0.016	0.38	0.016	0.023	0.016	0.023	0.032	0.19	
<i>Peptostreptococcus</i> sp.	1999	9	5	0.19	256.0	0.032	8.0	0.016	0.047	0.125	1.0	
	2000	44	1	256.0	256.0	0.032	0.38	0.023	0.75	1.0	1.0	
	2001	44	12	12.0	256.0	0.47	0.5	0.023	0.19	0.047	0.19	
Gram-positive rods ^c	1999	2	0	4.0	256.0	0.094	256.0	0.016	0.016	0	0	
	2000	6	1	6.0	256.0	0.125	1.5	0.0125	1.0	2.0	2.0	
	2001	3	1	1.5	1.5	1.5	3.0	0.47	0.19	0.125	0.125	

^a β -lactamase-negative strains.

^b β -lactamase-positive strains.

^c *Clostridium* sp., *Propionibacterium* sp., *Eubacterium* sp.

Table 3
The differences in the Defined Daily Doses per 1000 inhabitants annually (DDD/1000) from 1999 to 2001 in Estonia

Antibiotic	DDD/1000			Consumption dynamics
	1999	2000	2001	
Metronidazole	0.885	0.873	0.816	Stable
Clindamycin	0.025	0.040	0.053	Increased
Penicillin ^a	0.491	0.742	0.412	Variable
Ampicillin/sulbactam	0.257	0.395	0.505	Increased

^a Includes benzylpenicillin, phenoxymethylpenicillin, benzathin benzylpenicillin, and procain penicillin.

Resistance Surveillance System (EARSS) has monitored the levels of resistance among aerobic bacteria since 1998. EARSS results show that antibiotic resistance of *Streptococcus pneumoniae* to penicillin is correlated with the use of β -lactam antibiotics and macrolides both at the state and at the European level [6]. Seppälä et al. [7] found a similar correlation between the usage and resistance of erythromycin to *Streptococcus pyogenes*. Such information is not yet available for anaerobic bacteria. For example, in Europe the resistance pattern of aerobes and *Helicobacter pylori* is very variable [6,8]. These differences may be due to antibiotic pressure and the country-specific drug usage as well as different resistance mechanisms for a single group of bacteria. Little or no such data is available regarding the

resistance pattern of anaerobic bacteria in Eastern European countries whatsoever.

In our study, metronidazole resistance among Gram-negatives was not observed despite the relatively high consumption of this antimicrobial agent in Estonia. This was not the anticipated result; we expected that the intensive use of this antibiotic within Estonia would influence the microbial resistance pattern as suggested by other authors for other regions [6,7]. Up to now most data report antimicrobial activity of metronidazole against Gram-negative anaerobes [3,9]. It has been noted that resistance to this antibiotic among *B. fragilis* strains is a cause of treatment failures [10].

In the present study, there was an incongruity between the relatively high resistance and the low




Fig. 1. The total resistance of anaerobic bacteria to antibiotics (%) in relation with the rate of usage (DDD/1000).

consumption of clindamycin. A rise in resistance to clindamycin was noted in the *Bacteroides fragilis* group and also among *Clostridium* sp. and anaerobic cocci [3,11]. Only ampicillin/sulbactam demonstrated excellent activity in vitro against all anaerobes. Nevertheless, the consumption of ampicillin/sulbactam was higher than that of clindamycin, and increased two-fold from 1999 to 2001, the resistance pattern decreased in three consecutive years. Likewise, there is an incongruity between the resistance and the consumption of penicillin. Despite low consumption of penicillin, the resistance pattern was high for 1999 and 2000. The *B. fragilis* group in addition to certain *Clostridium* and *Fusobacterium* species are resistant to β -lactam antimicrobial agents primarily due to β -lactamase production. β -Lactamase production was common in different anaerobic species throughout the 3-year period studied. However, several β -lactamase-negative *Fusobacterium* strains appeared resistant to penicillin indicating some other resistance mechanisms [12]. To summarize, we did not observe a relationship between the changes in antibiotic consumption (DDD/1000) rate and the resistance pattern of anaerobic bacteria to metronidazole, clindamycin, penicillin and ampicillin/sulbactam during a 3-year period. One reason may be that anaerobic infections are predominantly derived from the host's own indigenous microflora, which is relatively stable [13–15]. Another explanation may be that the

effect of antibiotic pressure on indigenous microflora acts slowly. We could hypothesize that the resistance rate of anaerobes may correlate with the drug use of the patients from their date of birth to the testing period, and also with the antibiotic consumption of their parents.

High resistance to penicillin and among some species also to clindamycin is similar to the global trend and suggests limited use of those antibiotics in empirical treatment. Therefore, monitoring of local susceptibility patterns may be necessary for the selection of initial empirical therapy.

Acknowledgements

We are grateful to Lii Rootslane, the Estonian State Agency of Medicines, for co-operation, and to Sean Hynes, for advice.

References

- [1] Finegold SM. Overview of clinically important anaerobes. *Clin Infect Dis* 1995;20(Suppl 2):S205–7.
- [2] McGowan Jr JE. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? *Infect Control Hosp Epidemiol* 1994;2:691–5.
- [3] Aldridge KE, Ashcraft D, Cambre K, Pierson CL, Jenkins SG, Rosenblatt JE. Multicenter survey of the changing in vitro

- antimicrobial susceptibilities of clinical isolates of *Bacteroides fragilis* group, *Prevotella*, *Fusobacterium*, *Porphyromonas*, and *Peptostreptococcus* species. *Antimicrob Agents Chemother* 2001;4:1238–43.
- [4] Sebald M. Genetic basis for antibiotic resistance in anaerobes. *Clin Inf Dis* 1994;18(Suppl 4):S297–304.
- [5] Summanen P, Baron EJ, Citron D, Strong C, Wexler HM, Finegold SM. *Wadsworth anaerobic bacteriology manual*, 5th ed. Belmont, CA: Star Publishing Company; 1993.
- [6] Bronzwaer SLAM, Cars O, Buchholz U, Mölstad S, Goettsch W, Veldhuijzen IK, Kool JL, Sprenger MJW, Degener JE. Participants in the European Antimicrobial Resistance Surveillance System. A European study on the relationship between antimicrobial use and antimicrobial resistance. *Emerging Infect Dis* 2002;8:1–10.
- [7] Seppälä H, Nissinen A, Järvinen H, et al. Resistance to erythromycin in group a streptococci. *New Engl J Med* 1992;326:292–7.
- [8] Megraud F, Lehn N, Lind T, Bayerdörffer E, O'Morain C, Spiller R, Unge P, van Zanten SV, Wrangstadh M, Burman CF. Antimicrobial susceptibility testing of *Helicobacter pylori* in a large multicenter trial: the MACH 2 study. *Antimicrob Agents Chemother* 1999;11:2747–52.
- [9] Betriu C, Gomez M, Palau ML, Sanchez A, Picazo JJ. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfe-trinem, quinupristin-dalfopristin) against *Bacteroides fragilis* group: comparison with the activities of 14 other agents. *Antimicrob Agents Chemother* 1999;43:2320–2.
- [10] Rotimi VO, Khouseed M, Brazier JS, Jamal WY, Khodakhast FB. *Bacteroides* species highly resistant to metronidazole: an emerging clinical problem? *Clin Microbiol Infect* 1999;5:166–9.
- [11] Panigrahi D, Rotimi VO, Dhar R, Chugh TD, Dhar PM, Ghali A, Saad A, Sanyal SC, Varghese TL. Anaerobic bacterial flora of intra-abdominal infections and their antimicrobial susceptibility pattern in Kuwait. *Anaerobe* 2001;7:291–5.
- [12] Tuner K, Wexler HM, Reeves D, Finegold SM. Penicillin-binding proteins in *Fusobacterium* species. *Anaerobe* 1996;2:155–6.
- [13] Hoverstad T, Bjornekleit A, Fausa O, Midtvedt T. Short-chain fatty acids and bacterial overgrowth of the jejunum. *Scand J Gastroent* 1984;19(Suppl 98):43.
- [14] Midtvedt T. Influence of antibiotics on biochemical intestinal microflora-associated characteristics in man and animal. In: Gillisen G, Opferbach W, Peters G, Pulverer G, editors. *The influence of antibiotics on the host-parasite relationship III*. Springer-Verlag, Berlin: Heidelberg; 1989. p. 209–15.
- [15] Mättö J, Saarela M, von Troil-Linden B, Könönen E, Jousimies-Somer H, Torkko H, Alaluusua S, Asikainen S. Distribution and genetic analysis of oral *Prevotella intermedia* and *nigrescens*. *Oral Microbiol Immunol* 1996;11:96–102.